Citigroup has initiated coverage on Spyre Therapeutics Inc (SYRE) with a Buy rating, marking the firm's first assessment of the biotechnology company's investment potential. This action, taken on December 16, 2025, reflects Citigroup's analysis of Spyre's business dynamics and growth prospects.
Headquartered in Waltham, Massachusetts, Spyre Therapeutics focuses on developing next-generation human enzyme therapeutics aimed at treating rare and high-burden diseases. The company, which went public on April 7, 2016, is currently advancing several investigational therapies, including its lead candidate, SPY001. This fully human monoclonal antibody is designed to selectively bind to the a4b7 integrin for the treatment of inflammatory bowel disease (IBD).
As of the latest financial snapshot, Spyre Therapeutics has a market capitalization of $2.1 billion and reported an earnings per share (EPS) of -4.43 for the trailing twelve months. The company has upcoming earnings reports scheduled, with EPS estimates of -0.61 on August 3, 2026, and -0.59 on May 6, 2026.
Analyst consensus currently stands at a Buy rating, with Citigroup's initiation contributing to a total of 10 Strong Buy and 8 Buy ratings among 19 analysts covering the stock. Recent analyst actions include an upgrade from Jones Trading and a new Buy rating from Deutsche Bank, underscoring growing confidence in Spyre's potential within the biotechnology sector.
Analyst ratings can provide valuable insights, but they are based on assumptions that may not always materialize. Investors are encouraged to consider a variety of factors, including company fundamentals and industry trends, when evaluating investment opportunities.